Skip to main content
Premium Trial:

Request an Annual Quote

Eureka Genomics Reels in $3.7M

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Eureka Genomics has netted $3.7 million in financing through a private round that included individuals and undisclosed angel investors.

The Hercules, Calif.-based company said today that it plans to use the funding to advance its studies of novel microorganisms linked to specific cancers and other diseases, and to boost sales and marketing for its high-throughput sequencing data and bioinformatics service businesses.

"This funding will support the advancement of our lead programs in colorectal cancer, lymphoma, and cardiovascular disease," Eureka Genomics COO and Co-founder Didier Perez said in a statement. "Our advanced next-generation sequencing and bioinformatics capabilities have already resulted in the discovery of unique microbial associations with disease in animals and plants, and we are working to extend our discoveries to humans."

He added that the firm intends to add new partners over the coming year, which would include corporate collaborators for the co-development and commercialization of vaccines and diagnostics based on Eureka's discoveries.

Names of the investors in this round of funding were not disclosed.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.